Novartis To Pay $729M To End 2 FCA Kickback Accusations

Law360 (July 1, 2020, 11:53 PM EDT) -- Novartis Pharmaceuticals Corp. has agreed to pay more than $729 million to end two separate sets of allegations from the U.S. Department of Justice that it violated the False Claims Act through companywide kickback schemes to pump up prescriptions, the agency said Wednesday.

Swiss drugmaker Novartis will pay $729 million to settle civil kickback allegations brought by the U.S. Department of Justice. (AP Photo/Ahn Young-joon) In one deal, signed by the U.S. Attorney's Office for the Southern District of New York, the drugmaker agreed to pay $678 million — including $38.4 million under the Civil Asset Forfeiture Statute and $48.1 million to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!